Phenomenon of new drugs on the Internet: The case of ketamine derivative methoxetamine

Human Psychopharmacology

Volumn 27, Issue 2, 2012, Pages 145-149

  Corazza, Ornella ^a,b   Schifano, Fabrizio ^a   Simonato, Pierluigi ^a   Fergus, Suzanne ^a   Assi, Sulaf ^a   Stair, Jacqueline ^a   Corkery, John ^a   Trincas, Giuseppina ^a   Deluca, Paolo ^b   Davey, Zoe ^b   Blaszko, Ursula ^b   Demetrovics, Zsolt ⁱ   Moskalewicz, Jacek ^j   Enea, Aurora ^a   Mervo, Barbara ⁱ   Di Furia, Lucia ^h   Farre, Magi ^f   Flesland, Liv ^d   Pasinetti, Manuela ^a   Pezzolesi, Cinzia ^a   Pisarska, Agnieszka ^j   Shapiro, Harry ^c   Siemann, Holger ^e   Skutle, Arvid ^d   Di Melchiorre, Giuditta ^a   Sferrazza, Elias ^a   Torrens, Marta ^f   Van Der Kreeft, Peer ^g   Zummo, Daniela ^a   Scherbaum, Norbert ^e   more..

^a UNIVERSITY OF HERTFORDSHIRE   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c DrugScope   (United Kingdom)

^d Bergen Clinics Foundation   (Norway)

^e UNIVERSITY OF DUISBURG ESSEN   (Germany)

^f Department of Anaesthesiology and Intensive Care Medicine   (Spain)

^g De Sleutel   (Belgium)

^h Servizio Salute Regione Marche   (Italy)

ⁱ National Institute for Drug Prevention   (Hungary)

^j Institute of Psychiatry and Neurology (IPIN)   (Poland)

more..

Author keywords

designer drugs; Internet monitoring; ketamine; methoxetamine; research chemicals

Indexed keywords

4 CHLORO 2,5 DIMETHOXYPHENETHYLAMINE; 5,6 METHYLENEDIOXY 2 AMINOINDANE; ALPHA METHYLTRYPTAMINE; DESIGNER DRUG; KETAMINE; LYSERGIDE; METHOXETAMINE; NEW DRUG; RECREATIONAL DRUG; UNCLASSIFIED DRUG;

APHASIA; ARTICLE; CHEMICAL MODIFICATION; CHEMICAL STRUCTURE; COGNITIVE DEFECT; CONFUSION; CYSTALGIA; DEPRESSION; DISSOCIATIVE DISORDER; DIZZINESS; DRUG ABUSE; DRUG CLASSIFICATION; DRUG CONTAMINATION; DRUG COST; DRUG EFFECT; DRUG INFORMATION; DRUG MANUFACTURE; DRUG MARKETING; DRUG MECHANISM; HALLUCINATION; HUMAN; INFORMATION TECHNOLOGY; INSOMNIA; INTERNET; KIDNEY PAPILLA NECROSIS; LIVER DYSFUNCTION; MONITORING; ONLINE SYSTEM; PRIORITY JOURNAL; PSYCHOPHARMACOLOGY; RESTLESSNESS; SUBSTANCE ABUSE; SUICIDE ATTEMPT; SYSTEMATIC REVIEW; URETER OBSTRUCTION; WITHDRAWAL SYNDROME;

CYCLOHEXANONES; CYCLOHEXYLAMINES; DESIGNER DRUGS; HALLUCINOGENS; HUMANS; INTERNATIONAL COOPERATION; INTERNET; KETAMINE; PUBLIC HEALTH; STREET DRUGS; SUBSTANCE-RELATED DISORDERS; TIME FACTORS;

EID: 84858059961     PISSN: 08856222     EISSN: 10991077     Source Type: Journal    
DOI: 10.1002/hup.1242     Document Type: Article

References (35)

1. Bluelight. 2010; 2011. Bluelight forum, Retrieved June 1, 2011, from http://www.bluelight.ru
2. Bonta IL,. 2004. Schizophrenia, dissociative anaesthesia and near-death experience; three events meeting at the NMDA receptor. Med Hypotheses 62 (1): 23-28. (Pubitemid 38200001)
3. BulkResearchChemicals. 2011. Bulk research chemicals - methoxetamine price. Retrieved June 1, 2011 from. http://bulkresearchchemicals.com.
4. Corazza O,. 2010. Exploring space consciousness other dissociative experiences: a Japanese perspective. JCS 17: 173-190.
5. Corazza O, Schifano F,. 2010. Near-death states reported in a sample of 50 misusers. Subst Use Misuse 45 (6): 916-924.
6. Corazza O, Davey Z, Deluca P, et al,. 2010. Le nuove potenzialitA della prevenzione digitale in materia di nuove droghe: il ruolo del Recreational Drugs European Network. Dip Pat 2: 43-46.
7. Corazza O, Schifano F, Farre M, et al,. 2011. Designer drugs on the Internet: a phenomenon out-of-control? The emergence of hallucinogenic drug Bromo-Dragonfly. Curr Clin Pharmacol 6 (2): 125-129.
8. Coull J, Morgan H, Cambridge V, et al,. 2011. Ketamine perturbs perception of the flow of time in healthy volunteers. Psychopharmacology: 1-14.
9. Davies S, Wood DM, Smith G, et al,. 2010. Purchasing 'legal highs' on the Internet - is there consistency in what you get? QJM 103 (7): 489-493.
10. Dillon P, Copeland J, Jansen K,. 2003. Patterns of use and harms associated with non-medical ketamine use. Drug Alcohol Depend 69 (1): 23-28. (Pubitemid 36110459)
11. Drugs-Forum. 2011. Drug forum, Retrieved June 1 2011, from. http://www.drugs-forum.com
12. EMCDDA. 2010. EMCDDA report 2010: the state of the drugs problem in Europe, European Monitoring Centre for Drugs and Drug Addiction.
13. Enarson M, Hays H, Woodroffe MA,. 1999. Clinical experience with oral ketamine. J Pain Symptom Manage 17 (5): 384-386. (Pubitemid 29239531)
14. Erowid. 2010; 2011. Erowid, Retrieved June 1, 2011, from
15. Eurobarometer. 2008. Young people and drugs: analytical report. E. Commission.
16. Fletcher P, Honey GD,. 2006. Schizophrenia, ketamine and cannabis: evidence of overlapping memory deficits. Trends Cogn Sc 10 (4): 167-174.
17. Hipforums. 2011. Hip forums, Retrieved June 1, 2011, from http://www.hipforums.com
18. Jansen KLR,. 1989. Near-death experiences and the NMDA receptor. BMJ 298: 1708.
19. Jansen KLR,. 2001. Ketamine: Dreams and Realities. Sarasota: MAPS.
20. LegalHighsGuide. 2011. Legal highs guide Retrieved June 1, 2011 from http://www.legalhighsguide.com
21. Methoxetamine. 2011. Methoxetamine, Retrieved June 1 2011, from http://www.methoxetamine.co.uk
22. Moore J, Turner DC, Corlett PR, et al,. 2011. Ketamine administration in healthy volunteers reproduces aberrant agency experiences associated with schizophrenia. Cogn Neuropsych 16 (4): 364-381.
23. Morgan HL, Turner D, Corlett PR, et al,. 2011. Exploring the impact of ketamine on the experience of illusory body ownership. Biol Psychiatry 69 (1): 35-41.
24. Psychonaut. 2010. Psychonaut forum, Retrieved June 1, 2011, from. http://www.purechemicals.co.uk.
25. Purechemicals. 2010. Purechemicals: methoxetamine, Retrieved June 1, 2011, from. http://www.purechemicals.net.
26. PureChemicals. 2011. Research chemicals: methoxetamine, Retrieved June 1 2011, from. http://www.purechemicals.net.
27. PureChems. 2011. Pure chemicals - methoxetamine price, Retrieved June 1 2011, from. http://www.purechems.net.
28. Ramsey J, Dargan PI, Smyllie M, et al,. 2010. Buying 'legal' recreational drugs does not mean that you are not breaking the law. QJM 103 (10): 777-783.
29. Schifano F, Deluca, P, Baldacchino A, et al,. 2006. Drugs on the web; the Psychonaut 2002 EU project. Prog Neuropsychopharmacol Biol Psychiatry 30 (4): 640-646. (Pubitemid 43732330)
30. Schifano F, Corkery J, Oyefeso A, Tonia T, Ghodse AH,. 2008. Trapped in the 'K-hole'; overview of deaths associated with ketamine misuse in the UK (1993-2006). J Clin Psychopharmacol 28: 114-116.
31. Schifano F, Corazza O, Deluca P, et al,. 2009. Psychoactive drug or mystical incense? Overview of the online available information on spice products. Int J Cult Mental Health 2 (137-44).
32. Viceland. 2011. Interview whit a ketamine chemist. Viceland, Retrieved June 1 2011, from http://www.viceland.com/int/v18n2/htdocs/interviewwith- ketamine-chemist-704.php
33. Wood D, Cottrell A, Baker SC, et al,. 2011. Recreational ketamine: from pleasure to pain. BJU Intern 107 (12): 1881-1884.
34. YouTube.com. 2011a. Methoxetamine, research chemical. Retrieved July 1, 2011 from. http://www.youtube.com/watch?v=-gIalok602E&NR=1.YouTube.com
35. YouTube.com. 2011b. Pop star talks about methoxetamine (research chemicals). Retrieved July 1, 2011 http://www.youtube.com/watch?v=XBlMUnzcf-4..